CYB210010

CYB210010 (2C-T-TFM) is a lesser-known psychedelic drug related to compounds such as 2C-T and 2C-T-21. Alexander Shulgin attempted to synthesise this compound in the 1990s, and mentions it in his book PiHKAL under the entry for 2C-T-21, but was unsuccessful in producing a key intermediate and never assigned it a 2C-T number. This compound was ultimately first synthesised by Geoffrey Varty and colleagues at Irish biopharmaceutical company Cybin in 2023. It has a Ki of 0.35 nM at 5-HT2A, and an EC50 of 4.1 nM at 5-HT2A and 7.3 nM at 5-HT2C, compared to 88 nM at 5-HT2B. It is a potent, selective, long acting and orally active agonist for the 5-HT2A and 5-HT2C receptors and produces psychedelic-like responding in several different animal species. It is not known to have been tested in humans.